Literature DB >> 15790991

Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

M Decramer1, R Gosselink, M Rutten-Van Mölken, J Buffels, O Van Schayck, P-A Gevenois, R Pellegrino, E Derom, W De Backer.   

Abstract

Recently performed long term trials have enhanced the insight into the assessment of progression of COPD. The present review focuses on the initial assessment of COPD in general practice and the assessment of disease progression. Several variables may be used to assess this progression, all of which are associated with significant methodological problems. Finding the appropriate mix of outcome measures to capture all aspects of disease progression is a significant challenge.

Entities:  

Mesh：

Year:  2005        PMID： 15790991      PMCID： PMC1747360          DOI： 10.1136/thx.2004.028712

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  72 in total

Review 1.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  Early detection of COPD in a high-risk population using spirometric screening.

Authors:  J Zieliñski; M Bednarek
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

3.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

6.  Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial.

Authors:  T Troosters; R Gosselink; M Decramer
Journal:  Am J Med       Date:  2000-08-15       Impact factor: 4.965

Review 7.  Toward a consensus definition for COPD exacerbations.

Authors:  R Rodriguez-Roisin
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

8.  Pharmacoeconomic evaluation of COPD.

Authors:  D E Hilleman; N Dewan; M Malesker; M Friedman
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

9.  [Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study].

Authors:  R Rychlik; T Pfeil; D Daniel; B Pfeil; O Mast; I Thate-Waschke; J Lorenz
Journal:  Dtsch Med Wochenschr       Date:  2001-03-30       Impact factor: 0.628

10.  The costs of treating COPD in the United States.

Authors:  S A Strassels; D H Smith; S D Sullivan; P S Mahajan
Journal:  Chest       Date:  2001-02       Impact factor: 9.410
View more
  6 in total

1.  At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Authors:  Fernando J Martinez; MeiLan K Han; James P Allinson; R Graham Barr; Richard C Boucher; Peter M A Calverley; Bartolome R Celli; Stephanie A Christenson; Ronald G Crystal; Malin Fagerås; Christine M Freeman; Lars Groenke; Eric A Hoffman; Mehmet Kesimer; Kostantinos Kostikas; Robert Paine; Shahin Rafii; Stephen I Rennard; Leopoldo N Segal; Renat Shaykhiev; Christopher Stevenson; Ruth Tal-Singer; Jørgen Vestbo; Prescott G Woodruff; Jeffrey L Curtis; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

2.  Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.

Authors:  Giulia Veronesi; Eva Szabo; Andrea Decensi; Aliana Guerrieri-Gonzaga; Massimo Bellomi; Davide Radice; Stefania Ferretti; Giuseppe Pelosi; Matteo Lazzeroni; Davide Serrano; Scott M Lippman; Lorenzo Spaggiari; Angela Nardi-Pantoli; Sergio Harari; Clara Varricchio; Bernardo Bonanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-12-16

3.  A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.

Authors:  Charles K N Chan; François Maltais; Chris Sigouin; Jennifer M Haddon; Gordon T Ford
Journal:  Can Respir J       Date:  2007 Nov-Dec       Impact factor: 2.409

4.  A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Floortje E van Nooten; Marion Lindemann; Manfred Caeser; Peter M A Calverley
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

Authors:  A-B Tonnel; T Perez; J-M Grosbois; C Verkindre; M-L Bravo; M Brun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

6.  Evaluation of the sustaining effects of Tai Chi Qigong in the sixth month in promoting psychosocial health in COPD patients: a single-blind, randomized controlled trial.

Authors:  Aileen W K Chan; Albert Lee; Diana T F Lee; Janet W H Sit; S Y Chair
Journal:  ScientificWorldJournal       Date:  2013-10-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.